Eli ​Lilly raised its annual profit and ​revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand ​for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first results since launching oral GLP-1 pill Foundayo.